| Literature DB >> 18516223 |
Alun R Barnard1, Patrick M Nolan.
Abstract
Progress in unravelling the cellular and molecular basis of mammalian circadian regulation over the past decade has provided us with new avenues through which we can explore central nervous system disease. Deteriorations in measurable circadian output parameters, such as sleep/wake deficits and dysregulation of circulating hormone levels, are common features of most central nervous system disorders. At the core of the mammalian circadian system is a complex of molecular oscillations within the hypothalamic suprachiasmatic nucleus. These oscillations are modifiable by afferent signals from the environment, and integrated signals are subsequently conveyed to remote central neural circuits where specific output rhythms are regulated. Mutations in circadian genes in mice can disturb both molecular oscillations and measurable output rhythms. Moreover, systematic analysis of these mutants indicates that they can express an array of abnormal behavioural phenotypes that are intermediate signatures of central nervous system disorders. Furthermore, the response of these mutants to psychoactive drugs suggests that clock genes can modify a number of the brain's critical neurotransmitter systems. This evidence has led to promising investigations into clock gene polymorphisms in psychiatric disease. Preliminary indications favour the systematic investigation of the contribution of circadian genes to central nervous system disease.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18516223 PMCID: PMC2295261 DOI: 10.1371/journal.pgen.1000040
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Figure 1The Mammalian Molecular Circadian Oscillator.
The molecular circadian oscillator incorporates numerous transcriptional and posttranslational elements. Disruptions in many of the individual circadian elements in mice can lead to behavioural disturbances that mirror endophenotypes in human neurological and psychiatric disorders. Moreover, some studies have established circadian gene polymorphisms in psychiatric conditions and mutations in behavioural syndromes (see text for details). The central component of the figure depicts the core mammalian circadian feedback loop. CLOCK(or NPAS2):BMAL1 heterodimers drive the transcription of multiple genes (Cry1/2, Per1-3, Rev-Erba/b, Rora/b/c, multiple CCGs) through E-box elements. Nuclear accumulation of CRY and PER proteins can inhibit CLOCK:BMAL1-mediated transcription by directly interacting with the complex (black bar–ended arrow). As PER and CRY levels fall, the negative repression is lifted and CLOCK:BMAL1-driven transcription re-occurs. In an additional stabilising loop, REV-ERB and ROR proteins co-regulate the transcription of Bmal1 by competing for RREs in its promoter sequence. Rhythmic output of the clock is achieved through E-box elements in CCG which can impact a range of cell processes and physiology. The stability and subcellular localisation of circadian proteins is highly regulated by kinases and phosphatases (inset box). Although not entirely understood, the phosphorylation state of circadian proteins can affect their cellular localisation and/or stability. Mutations affecting the stability of Per proteins can accelerate the molecular clock in humans, leading to the inherited syndrome familial advanced sleep phase syndrome (FASPS).
Figure 2The Circadian System and the Mammalian Brain.
The SCN acts as a “master” clock, sending neuronal and humoral output to a number of regions in the CNS. The SCN can passively drive rhythmicity in these regions, or nuclei may themselves have their own automomous clocks. Within the SCN, every cell is a potentially independent oscillator unit. Extensive intra-SCN signalling is used to synchronise the rhythms of multiple cells. Entrainment is a process whereby environmental stimuli can alter the timing or phase of central rhythms so that they are coincidental with the prevailing daily cycle (far left). Time cues reach the SCN via several pathways involving intermediate brain areas. Some of these relay nuclei may contain their own oscillators and/or have rhythms in their function (blue and orange arrows and oscillators). Others may not have rhythmic function (green arrow). Extra-SCN oscillators may directly utilise time cues (blue and orange oscillators) or may rely solely on the SCN to synchronise/entrain rhythms (lilac arrows to grey oscillators). These oscillators may also provide feedback which impacts on the operation of the SCN (grey return arrows). In addition, extra-SCN oscillators may drive/influence rhythmicity in other brain areas (smaller grey oscillator) and communicate with each other independently from the SCN (reciprocal grey arrows). Within the CNS, some neurotransmitters/neuromodulators involved in signalling are indicated. The overall output of this complex system (large red arrow) creates the daily rhythmicity seen in a range of neurological functions and behaviours (far right). There is a wider communication with clock/oscillator units throughout the entire body. However, these so-called “peripheral” oscillators and their actions are not shown here.
Rhythm/Sleep Endophenotypes in Human CNS Disease and in Mouse Models.
| Human Disease or Condition | Disturbed Rhythm/Sleep Endophenotype | Relevant Phenotypes in Mouse Models |
| Familial advanced sleep phase syndrome (FASPS) | Early sleep and wake times, shortened circadian rhythms | Mice expressing human mis-sense mutations in |
| Delayed sleep phase syndrome (DSPS) | Extreme evening preference, delayed phase of activity, sleep, core body temperature, and melatonin | No model. |
| Seasonal affective disorder (SAD) | Depressive symptoms occur during shorter winter days | No model. |
| Mood disorders (unipolar depression) and psychoses (schizophrenia, bipolar) | Depression. Increased sleep latency, impaired sleep continuity, phase advance in endogenous circadian system relative to sleep schedule, phase advances in growth hormone, plasma melatonin, increased plasma cortisol at night. All major affective disorders include circadian phase disturbances in sleep, activity, temperature, and hormone levels (for reviews see | No accurate mouse model. Mutants in serotonergic and dopaminergic systems show disturbances in circadian phase and/or sleep parameters |
| Autism spectrum disorders (ASD) | Longer sleep latency and greater sleep fragmentation. Abnormalities in circadian rhythm and mean concentration of plasma melatonin | Mice expressing a conditional deletion of |
| Down syndrome | Reduced sleep maintenance, sleep fragmentation, reduction in percent REM sleep, sleep apnea | Ts65Dn mouse mutant shows increased activity in the light phase, a reduction in rhythm amplitude, and a 4-h advance in the phase of activity |
| Smith-Magenis syndrome | Inverted rhythm of melatonin secretion | Heterozygous deletion mutant mice have a hypoactive phenotype and a significantly shorter circadian period |
| Prader-Willi syndrome | Sleep apnea, sleep-related and behavioural disturbances including daytime napping and excessive daytime sleepiness | Mice deficient for mage-like 2 gene (Magel2) have a reduced circadian activity amplitude with increased daytime activity |
| Parkinson disease (PD) | Sleep fragmentation, sleep apnea, REM sleep behaviour disorder, excessive daytime sleepiness | No recorded circadian or sleep disturbances in genetic mouse models |
| Huntington disease (HD) | Nocturnal awakening and progressive disintegration of daily activity rhythms | R6/2 mouse transgenic line has increased daytime and reduced nocturnal activity. Progresses to a complete disintegration of diurnal and circadian activity rhythms |
| Alzheimer disease (AD) | Fragmented sleep, increased nocturnal activity, and reduced daytime activity. Delayed phase in peak of daily activity | Alterations in sleep regulation and timing in Tg2576 |
| Aging | Sleep disturbances due to earlier wake time and reduced sleep consolidation. Partially attributed to age-related reduction in amplitude and advance in phase of circadian rhythms | Aging lengthens the period and reduces the amplitude of circadian activity rhythms. The onset of daily activity is significantly delayed and the variability of onset is increased |
| Prion diseases | Severe sleep abnormalities, progressive loss of circadian rest-activity, and melatonin rhythms | Increased sleep fragmentation and significantly longer circadian period in activity in prion protein null mutants |